| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Why I Am NOT Surprised When I Hear People Making 50 Percent Profit On a Trade - Overnight |
|
Main Subject - Why I Am NOT Surprised When I Hear People Making 50 Percent Profit On a Trade - Overnight
How do I know that this can happen? Simple: It has happened to me! Let me show you the play-by-play… Summary of tra According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product de: * Name of Company: Cemex (ticker:CX). * Opening Trade: Bought 20 contracts of CX on January 31, 2005 at $2. ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in 0 a contract (March 2005 expiration, Strike: 35). * Closing Trade: Sold 20 contracts of CX, two days later, on F lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ebruary 2, 2005 at $4.00 a contract for a profit of $1.6 a contract, or 40%. * Between the time I bought and sol here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe my options, the stock moved $1.32. This was my first time my options “popped” in such a short period of time. A “fr d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ak of nature” type of incident? I don’t think so! So why did this happen? Now I do admit, however, while I would love ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc to have all my trades profit this quickly, there is always a little luck when it comes to how quickly things move. B easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi t what was not due to luck were the reasons that I entered into this trade in the first place. Three factors led me nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically o believe that this setup looked ripe for the plucking. First: The trend is always your friend. This is a simple, y and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ et, often overlooked statement. Higher highs, and higher lows indicate an up-trending graph (I’ve circled the higher ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ows in the graph). The reason why this rule is overlooked is because people try to speculate - a stock can be beaten ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a own for so long that traders will start speculating when the stock will start to recover and start moving upwards. So dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod metimes it does, sometimes it doesn’t work this way. The gamble is this: if you are right, you catch the initial “pop cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin of momentum as there is usually a jump in price as the stock changes trend. Catch the beginning of a trend move, and tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen you can make big bucks, real fast. I don’t speculate. I trade on evidence that I can see, and measure. Trading shoul t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel d be winning on probabilities and evidence, not gambling. Trend is your friend. A very simple rule, but very importa ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust t. This example exemplifies this lesson. The second lesson, which we will go over next time, is a bit more juicier as y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products it involves a look into candlestick formations and these little guys can reveal when a set up is prime for profiting. . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de To read the next part of the article, please visit my webpage http://www.stockshaker.com, where we talk about profi elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ing in the stock market, as well as other great topics like: making money online, travel, food ... stuff that matters tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:What Is The Big Challenge With MLM? Employees' Poor Writing Skills Can Lead to Lost Profit
|